Business Wire

OH-PROCTER-&-GAMBLE

11.1.2021 16:02:36 CET | Business Wire | Press release

Share
Oral-B’s Virtual Experience at 2021 Consumer Electronics Show Puts the Power to Control Health in Consumers’ Hands with the Oral-B iO™

During a time when many things feel out of our control, people have taken stock of their health and are seeking ways to make a meaningful, positive impact – all from the comfort of home.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005188/en/

This year, at the 2021 Consumer Electronics Show (CES), Oral-B will highlight its commitment to powering the smallest daily habits, such as using an electric toothbrush, to create the biggest positive impact on the health of your whole body, whole family and the whole planet, through its first ever virtual experience.

Located within P&G’s LifeLab Everyday virtual platform, the virtual experience will highlight Oral-B iO, the brand’s most innovative toothbrush, reimagined and redesigned from the inside out to remove 100% more plaque than a manual toothbrush.

  • The unique dentist-inspired round brush head is designed to surround each tooth with its micro-vibrating bristles to reach below the gumline for a deep, professional clean feeling every day.
  • The bimodal smart pressure sensor is the first of its kind to provide positive brushing feedback, identifying and guiding users to brush in the optimal pressure range to protect gums and enamel.
  • The Linear Magnetic Drive System delivers controlled, consistent movements from the handle to brush tips, producing gentle micro-vibrations for a more enjoyable experience and efficiently transferring more energy directly to the bristle tips.
  • The Smart Display with Personalized Brushing Modes offers an intuitive interface that provides coaching and motivation throughout the cleaning process and features up to seven brush modes for a highly personalized experience.

And this all comes together with Artificial Intelligence Tracking via the Oral-B iO App. It provides real-time individual tracking and coaching, thanks to artificial intelligence informed by thousands of recorded brushing sessions. Oral-B iO has a simple and intuitive user interface that guides consumers through a two-minute brushing session with 3D teeth tracking to ensure a professional clean feeling every time.

Recently, Oral-B partnered with Scientific American to further explore and understand the new research and innovations transforming our understanding of the connection between oral health and overall health.

“Over 700 studies substantiate the notion that great oral health habits can be a simple step in improving one’s overall health,” explains Jeremy A. Abbate, VP & Publisher at Scientific American, “Gum disease is the mouth’s way of warning us of potentially more serious issues to come, so it’s important to heed those early warnings.”

Those warning signs can be as small as bleeding gums or tooth loss but can lead to more severe conditions such as heightened pregnancy complications, cognitive loss and more than double the risk of cardiovascular disease and diabetes.

In clinical tests, Oral-B iO provided a deeper cleaning of teeth and gums, allowing users to easily and effectively maintain oral health. Oral-B iO users experienced:

  • 100 percent healthier gums in just one week, when compared to manual toothbrushes
  • 6 times more plaque removal along the gumline, when compared to manual toothbrushes
  • 83 percent of gingivitis patients moved from unhealthy to healthy gums in eight weeks

Lisa Ernst, Senior Vice President, Research & Development, Oral Care stated, “An Oral-B electric toothbrush is a powerful first step in being proactive against the risks associated with gum disease. We give consumers the power to take control of their families’ health at home with Oral-B iO, which helps prevent and reduce gingivitis for the best gum health.”

In addition, P&G’s LifeLab Everyday will feature P&G Oral Care’s newest sustainability commitments to advance healthy oral care habits to transform the health of people while reducing our impact on our planet. Healthy habits for the environment mean a world where everyone respects our planet and its natural resources by:

  • Turning off the tap when brushing your teeth
  • Recycling packaging and products
  • Unplugging the toothbrush charger when not in use.

For more information on Oral-B iO, please visit oralb.com .

About Oral-B

Oral-B® is the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand includes manual and electric toothbrushes for children and adults, oral irrigators and interdental products, such as dental floss.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gain® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news .

About Procter & Gamble’s LifeLab Everyday:

At P&G’s LifeLab Everyday is a new virtual platform that reveals how innovation at Procter & Gamble is reinventing consumer experiences and making progress toward a better future for our society and our planet. The exhibit combines robust, consumer-based insights with breakthrough science inspired by how people live, work, play.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release

Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release

Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate

Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release

Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction

L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release

Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye